Breaking News

Immune Pharma, EpiCept to Merge

Will focus on antibody therapies for inflammatory diseases and cancer

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Immune Pharmaceuticals and EpiCept Corp. have entered into a merger agreement. The transaction is expected to close 1Q13, subject to customary closing conditions. The combined company will be called Immune Pharmaceuticals, Inc. and will be focused on developing antibody therapeutics and other targeted drugs for the treatment of inflammatory diseases and cancer. Immune’s lead product candidate, bertilimumab, is a fully human MAb currently in Phase II development for the treatment of ulcerative co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters